Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc.
Eli Lilly and Company
M.D. Anderson Cancer Center
BioNTech SE
Astellas Pharma Inc
Pfizer
Eikon Therapeutics
ModernaTX, Inc.
Verastem, Inc.
AstraZeneca
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Shenzhen Ionova Life Sciences Co., Ltd.
GI Innovation, Inc.
PMV Pharmaceuticals, Inc
Mayo Clinic
Tizona Therapeutics, Inc
Essen Biotech
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
University of Oklahoma
Riboscience, LLC.
Sairopa B.V.
NovoCure Ltd.
Jazz Pharmaceuticals
VM Oncology, LLC
Masonic Cancer Center, University of Minnesota
Memorial Sloan Kettering Cancer Center
Erasca, Inc.
University of Chicago
Eikon Therapeutics
Eikon Therapeutics
TuHURA Biosciences, Inc.
Erasca, Inc.
The University of Texas Health Science Center, Houston
Nectin Therapeutics Ltd
Qurient Co., Ltd.
University of Wisconsin, Madison
Medicenna Therapeutics, Inc.
Acepodia Biotech, Inc.
Phanes Therapeutics
CJ Bioscience, Inc.
Nykode Therapeutics ASA
GI Innovation, Inc.
UNICANCER
University of California, Davis
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)